Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (NASDAQ: ORGO) is a commercial-stage regenerative medicine company focused on advanced wound care and surgical biologics. The company entered the public markets in 2018 through a merger with Avista Healthcare Public Acquisition Corp, a blank-check vehicle sponsored by Avista Capital Holdings. Operating in the healthcare and medical devices sector, Organogenesis develops and commercializes products targeting chronic and acute wound management across hospital and outpatient settings. The company filed an 8-K with the SEC on August 6, 2026, under accession number 0001193125-26-338321. Sign up at SpacDesk for full filing history, sponsor profiles, and deep SPAC data on ORGO and thousands of other transactions.